CAS
EBS icon

Coppell Advisory Solutions’s Emergent Biosolutions EBS Stock Holding History

Coppell Advisory Solutions’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-161,307
Closed -$1.96M – 97
2025
Q4 		$1.96M Buy
+161,307
New +$1.73M 0.19% 104

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Coppell Advisory Solutions's EBS Position: Q1 2026 in Review

Coppell Advisory Solutions sold out of Emergent Biosolutions (EBS) in Q1 2026, closing a stake of 161,307 shares — an estimated $1.96M sold.

Coppell Advisory Solutions first reported a position in EBS in Q4 2025 and held it in 1 quarter. The position peaked at $1.96M in Q4 2025. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • Coppell Advisory Solutions reported no remaining Emergent Biosolutions position as of Q1 2026 after selling out during the quarter.
  • Coppell Advisory Solutions sold 161,307 Emergent Biosolutions shares in Q1 2026, an estimated $1.96M.
  • Coppell Advisory Solutions first reported a position in Emergent Biosolutions in Q4 2025 and held it in 1 quarter.
  • Coppell Advisory Solutions's Emergent Biosolutions position peaked at $1.96M in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Coppell Advisory Solutions's 13F filing for Q1 2026, filed 15 May 2026.